0      0

Product Theater: Exploring the ADA 2023 Standards of Care Recommendation for treating Diabetic Foot Ulcers (DFU) with Topical Oxygen Therapy (TOT)

‐ Feb 10, 2023 12:30pm

SPONSORED BY AOTI This presentation will first summarize the growing burden that DFUs impose on patients, caregivers, clinicians, and healthcare systems alike, as well as highlight how low-socioeconomic and racial minorities are disproportionally affected. The extensive body of RCT, RWE, Systematic Reviews and Meta Analyses supporting AOTI’s unique cyclical-pressurized Topical Wound Oxygen (TWO2) therapy will be reviewed, which provided the scientific basis for the recent evidence based “A“ grade adjunctive treatment recommendation. The application of TWO2 therapy will be demonstrated as to how it more sustainably heals DFUs and provides patients with more ulcer free days, resulting in significantly less hospitalizations and lower extremity amputations. The effect that TWO2 has, as a patient applied at-home therapy, on improving Access to Care and Health Equity, will also be explored. MIKE GRIFFITHS DPROF, DMS, CRT, FRSM, FCMI [https://ada.digitellinc.com/ada/live/24/page/175] Dr. Griffiths is a seasoned medical device executive who has been the CEO, Medical Director and Co-Founder of AOTI Inc. since 2006. Dr. Griffiths is a Fellow of both the Royal Society of Medicine and Chartered Management Institute. He holds a Doctorate in Medical Device Innovation and Entrepreneurship from Middlesex University, London, United Kingdom, a post-graduate Diploma in Management from Kingston University, United Kingdom, and several further engineering and clinical credentials, including that of a Certified Respiratory Therapist. Dr. Griffiths posses over 35 years of wound and critical care experience gained from a wide variety of roles throughout the globe, working with both start-ups and multinationals alike. Prior to starting AOTI, he was the co-founder and CEO of eVent Medical Ltd., a start-up venture in the critical care ventilation field, which was sold to the Kobayashi pharmaceutical company of Japan. Preceding eVent, Dr. Griffiths held various senior management positions at Mallinckrodt Inc., Nellcor Puritan Bennett Inc., and Hudson RCI, amongst others. Dr. Griffiths is also an active advocate in reducing stigma and achieving mental health equity as the Chairman of the International Bipolar Foundation. ------------------------- CONTACT INFORMATION: Amy Gray, RN, BSN, CWS Assoc. Director of Clinical Development Mobile: (423) 408-3822 Office: (760) 431-4700 Fax: (760) 683-3063 Email: amy.gray@aotinc.net Website: www.aotinc.net